35
Participants
Start Date
June 10, 2013
Primary Completion Date
October 9, 2019
Study Completion Date
October 9, 2019
Tocilizumab
Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants \< 30 kg) or 8 mg/kg (for participants \>/=30 kg) Q2W/Q3W/Q4W.
Hospital Gral de Niños Pedro Elizalde, Buenos Aires
Hospital Dr. Humberto Notti, Mendoza
Charité Campus; Virchow Klinikum Berlin, Berlin
Unidad de Reumatologia Rehabilitacion Integral; Centro Medico Del Angel, Mexicali
Hospital Ramon y Cajal ; Servicio de Reumatologia, Madrid
Hospital de La Paz; Unidad de Reumatologia Pediatrica, Madrid
Univ. Di Padova - Dip. Di Pediatria - Unita' Reumatol. Pediatrica, Padua
Asklepios Klinik; Zentrum für Allgemeine Pädiatrie und Neonatologie, Sankt Augustin
Children's Hospital Los Angeles; Division of Rheumatoogy, Los Angeles
SI Sceintific children health center RAMS, Moscow
Saint-Petersburg State; Pediatrics Medical Academy, Saint Petersburg
Rambam Medicl Center, Ruth Children Hospital, Haifa
Meir Medical center, Pediatrics, Kfar Saba
Schneider Children's Medical Center of Israel, Petah Tikva
Cincinnati Children'S Hospital Medical Center; Division of Rheumatology, Cincinnati
Alberta Children'S Hospital, Calgary
Irccs Ospedale Pediatrico Bambin Gesu - Dip. Di Medicina, Rome
Hospital Sant Joan De Deu; Servicio de Reumatologia Pediatrica, Barcelona
Royal Liverpool Childrens Hospital; Rheumatology, Liverpool
Hoffmann-La Roche
INDUSTRY